Tekrardan Hoşgeldiniz
Cointime'ın Hizmet Şartları'ini kabul etmek ve Cointime'ın Gizlilik Politikası'inin sizin için geçerli olduğunu onaylamak için "Giriş "a tıklayın.
Cointime’a Katıl
Çoktan Hesabın Var mı?
Cointime'ın <a class="underline" href="#term-of-service">Hizmet Şartları</a>'ini kabul etmek ve Cointime'ın a class="underline" href="#privacy-policy">Gizlilik Politikası</a>'inin sizin için geçerli olduğunu onaylamak için "page.Sign up "a tıklayın.
Giriş Yap
Kayıt Ol
Posta kutunuz
Gelen kutunuzu kontrol edin
Giriş yapmak için emaildeki bağlantıya tıklayın.
Kayıt olmak için emaildeki bağlantıya tıklayın.
Hypnion
company
About
Hypnion is a neuroscience drug discovery company.
- 51 - 100
Details
- Last Funding Type
- Series B
- Last Funding Money Raised
- $47.50M
- Industries
- Biotechnology,Health Diagnostics,Medical,Therapeutics
- Founded date
- Jan 1, 2000
- Number Of Employee
- 51 - 100
- Operating Status
- Active
Hypnion is a neuroscience drug discovery and development company that develops novel therapeutics for the treatment of central nervous system disorders. The company develops treatments for sleep- and wake-alertness disorders and circadian rhythm abnormalities.Hypnion offers SCORE-2004, a drug discovery platform that is able to measure drugs’ impact on sleep and wake parameters.Hypnion is acquired by Eli Lilly and Company.Hypnion was founded in 2000 and is based in Worcester, Massachusetts.
Funding Rounds
Number of Funding Rounds
Total Funding Amount
1
$47.50M
Hypnion has raised a total of
$47.50M
in funding over 2 rounds. Their latest funding was raised on
Mar 17, 2003 from a Series B round.
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Mar 17, 2003 | Series B | $47.50M | 1 | — | — | Detail |
Investors
Number of Lead Investors
Number of Investors
—
1
Hypnion is funded by 1 investors.
Coastview Capital
are the most recent investors.
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
|
|
— | Series B |
Share
Twitter
LinkedIn
Line
Facebook
Telegram
Email
Page Link
